Andrea Resovi

Dr. Andrea Resovi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Matrix Biology
Verified
Journal Article
Open access
ARAndrea Resovi
Andrea Resovi
DPDenise Pinessi
Denise Pinessi
GCGiovanna Chiorino
Giovanna Chiorino
GTGiulia Taraboletti
Giulia Taraboletti
The multifaceted action of thrombospondin-1 (TSP-1) depends on its ability to physically interact with different ligands, including structural components of the extracellular matrix, other matricellular proteins, cell receptors, growth factors, cytokines and proteases. Through this network, TSP-1 regulates the ligand activity, availability and structure, ultimately tuning the cell response to environmental stimuli in a context-dependent manner, contributing to physiological and pathological processes. Complete mapping of the TSP-1 interactome is needed to understand its diverse functions and to lay the basis for the rational design of TSP-1-based therapeutic approaches. So far, large-scale approaches to identify TSP-1 ligands have been rarely used, but many interactions have been identified in small-scale studies in defined biological systems. This review, based on information from protein interaction databases and the literature, illustrates current knowledge of the TSP-1 interactome map.

25 June 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ARAndrea Resovi
Andrea Resovi
MBMariaRosa Bani
MariaRosa Bani
LPLuca Porcu
Luca Porcu
AAAlessia Anastasia
Alessia Anastasia
LMLucia Minoli
Lucia Minoli
RGRaffaella Giavazzi
Raffaella Giavazzi
The clinical management of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of reliable biomarkers. This study investigated the value of soluble stroma‐related molecules as PDAC biomarkers. In the first exploratory phase, 12 out of 38 molecules were associated with PDAC in a cohort of 25 PDAC patients and 16 healthy subjects. A second confirmatory phase on an independent cohort of 131 PDAC patients, 30 chronic pancreatitis patients, and 131 healthy subjects confirmed the PDAC association for MMP7, CCN2, IGFBP2, TSP2, sICAM1, TIMP1, and PLG. Multivariable logistic regression model identified biomarker panels discriminating respectively PDAC versus healthy subjects (MMP7 + CA19.9, AUC = 0.99, 99% CI = 0.98–1.00) (CCN2 + CA19.9, AUC = 0.96, 99% CI = 0.92–0.99) and PDAC versus chronic pancreatitis (CCN2 + PLG+FN+Col4 + CA19.9, AUC = 0.94, 99% CI = 0.88–0.99). Five molecules were associated with PanIN development in two GEM models of PDAC (PdxCre/LSL‐KrasG12D and PdxCre/LSL‐KrasG12D/+/LSL‐Trp53R172H/+), suggesting their potential for detecting early disease. These markers were also elevated in patient‐derived orthotopic PDAC xenografts and associated with response to chemotherapy. The identified stroma‐related soluble biomarkers represent potential tools for PDAC diagnosis and for monitoring treatment response of PDAC patients. Synopsis Seven stroma‐related circulating biomarkers that discriminate between healthy subjects and pancreatic ductal adenocarcinoma (PDAC) in two different cohorts of patients have been identified and suggested as a potential diagnosis tool to monitor treatment efficacy in patients. Panels of biomarkers that improve the performance of CA19.9 in distinguishing i) PDAC from healthy subjects and ii) PDAC from chronic pancreatitis have been developed. Multivariable models confirmed their predictive accuracy at early stages of disease. The association of these biomarkers with the development of pre‐invasive disease in GEM models confirmed their potential to detect early stage lesions. The correlation of biomarker levels with tumor burden and drug response in patient‐derived PDAC xenograft models indicate their value to monitor treatment response and efficacy.

1 September 2016 in Matrix Biology
Verified
Journal Article
Closed access
DBDorina Belotti
Dorina Belotti
CCChiara Capelli
Chiara Capelli
ARAndrea Resovi
Andrea Resovi
MIMartino Introna
Martino Introna
GTGiulia Taraboletti
Giulia Taraboletti

23 May 2016 in Oncogene
Verified
Journal Article
Closed access
GMG B Martinelli
G B Martinelli
DOD Olivari
D Olivari
ACAndrea Re Cecconi
Andrea Re Cecconi
LTLaura Talamini
Laura Talamini
LOL Ottoboni
L Ottoboni
RPRosanna Piccirillo
Rosanna Piccirillo

1 December 2011 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
DBDorina Belotti
Dorina Belotti
CFChiara Foglieni
Chiara Foglieni
ARAndrea Resovi
Andrea Resovi
RGRaffaella Giavazzi
Raffaella Giavazzi
GTGiulia Taraboletti
Giulia Taraboletti

13 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
ARAndrea Resovi
Andrea Resovi
PBPatrizia Borsotti
Patrizia Borsotti
TCTommaso Ceruti
Tommaso Ceruti
APAlice Passoni
Alice Passoni
MZMassimo Zucchetti
Massimo Zucchetti
DBDorina Belotti
Dorina Belotti
The prominent desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC) is a determinant factor in tumor progression and a major barrier to the access of chemotherapy. The PDAC microenvironment therefore appears to be a promising therapeutic target. CCN2/CTGF is a profibrotic matricellular protein, highly present in the PDAC microenvironment and associated with disease progression. Here we have investigated the therapeutic value of the CCN2-targeting BLR100 and BLR200, two modified synthetic peptides derived from active regions of CCN3, an endogenous inhibitor of CCN2. In a murine orthotopic PDAC model, the two peptides, administered as monotherapy at low doses (approximating physiological levels of CCN3), had tumor inhibitory activity that increased with the dose. The peptides affected the tumor microenvironment, inhibiting fibrosis and vessel formation and reducing necrosis. Both peptides were active in preventing ascites formation. An increased activity was obtained in combination regimens, administering BLR100 or BLR200 with the chemotherapeutic drug gemcitabine. Pharmacokinetic analysis indicated that the improved activity of the combination was not mainly determined by the substantial increase in gemcitabine delivery to tumors, suggesting other effects on the tumor microenvironment. The beneficial remodeling of the tumor stroma supports the potential value of these CCN3-derived peptides for targeting pathways regulated by CCN2 in PDAC.